Mark L. Offerhaus
Corporate Officer/Principal bei Eco Investment Partners BV
Profil
Mark L.
Offerhaus is the founder of Eco Investment Partners BV (founded in 2005) and Micreos BV (founded in 2005).
At Micreos BV, he held the title of Chief Executive Officer from 2005 to 2023.
He also served as the Chief Executive Officer of Micreos Human Health BV from 2005 to 2023.
Prior to his founding roles, Mr. Offerhaus worked as a Director at Exponential Biotherapies, Inc. from 2001 to 2004.
He also held positions at ING Groep NV as a Principal and at Enuenu Life Insurance Co., Ltd.
as President.
Mr. Offerhaus obtained a graduate degree from the University of Leiden.
Aktive Positionen von Mark L. Offerhaus
| Unternehmen | Position | Beginn |
|---|---|---|
| Eco Investment Partners BV | Corporate Officer/Principal | 01.01.2005 |
Ehemalige bekannte Positionen von Mark L. Offerhaus
| Unternehmen | Position | Ende |
|---|---|---|
Micreos BV
 Micreos BV Pharmaceuticals: GenericHealth Technology Micreos BV develops phage-based products against specific dangerous bacteria. It offers human health, food safety, agriculture and animal health products. The company was founded by Mark Offerhaus and is headquartered in Wageningen, the Netherlands. | Vorstandsvorsitzender | 01.06.2023 |
Micreos Human Health BV
 Micreos Human Health BV BiotechnologyHealth Technology Micreos Human Health BV operates as biotechnology company, which engages in the provision of anti-bacterial products. It develops Gladskin, a technology that targets the harmful Staphylococcus aureus-bacterium, and eaves the good bacteria - essential for a healthy skin. The company is headquartered in The Hague, the Netherlands. | Vorstandsvorsitzender | 01.06.2023 |
Exponential Biotherapies, Inc.
 Exponential Biotherapies, Inc. Pharmaceuticals: MajorHealth Technology Exponential Biotherapies, Inc. discovers and develops drugs. It provides small molecule drugs to treat an inflammatory disorders, such as acute kidney injury, septic shock, radiation sickness, and avian influenza infections. The company was founded on July 31, 1996 and is headquartered in New York, NY. | Direktor/Vorstandsmitglied | 01.01.2004 |
| ING GROEP N.V. | Corporate Officer/Principal | - |
Enuenu Life Insurance Co., Ltd.
 Enuenu Life Insurance Co., Ltd. Life/Health InsuranceFinance Part of ING Groep NV, Enuenu Life Insurance Co., Ltd. is a company based in Tokyo, Japan. The CEO of the Japanese company is Frank Eijsink. | Präsident | - |
Ausbildung von Mark L. Offerhaus
| University of Leiden | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| ING GROEP N.V. | Finance |
| Private Unternehmen | 5 |
|---|---|
Exponential Biotherapies, Inc.
Exponential Biotherapies, Inc. Pharmaceuticals: MajorHealth Technology Exponential Biotherapies, Inc. discovers and develops drugs. It provides small molecule drugs to treat an inflammatory disorders, such as acute kidney injury, septic shock, radiation sickness, and avian influenza infections. The company was founded on July 31, 1996 and is headquartered in New York, NY. | Health Technology |
Micreos BV
Micreos BV Pharmaceuticals: GenericHealth Technology Micreos BV develops phage-based products against specific dangerous bacteria. It offers human health, food safety, agriculture and animal health products. The company was founded by Mark Offerhaus and is headquartered in Wageningen, the Netherlands. | Health Technology |
Enuenu Life Insurance Co., Ltd.
Enuenu Life Insurance Co., Ltd. Life/Health InsuranceFinance Part of ING Groep NV, Enuenu Life Insurance Co., Ltd. is a company based in Tokyo, Japan. The CEO of the Japanese company is Frank Eijsink. | Finance |
Micreos Human Health BV
Micreos Human Health BV BiotechnologyHealth Technology Micreos Human Health BV operates as biotechnology company, which engages in the provision of anti-bacterial products. It develops Gladskin, a technology that targets the harmful Staphylococcus aureus-bacterium, and eaves the good bacteria - essential for a healthy skin. The company is headquartered in The Hague, the Netherlands. | Health Technology |
| Eco Investment Partners BV |
